

## **RELMADA THERAPEUTICS APPOINTS MICHAEL BECKER AS SENIOR VICE PRESIDENT OF FINANCE AND CORPORATE DEVELOPMENT**

*Company Broadens and Strengthens its Senior Leadership Team*

**New York, NY November 4, 2014** Relmada Therapeutics, Inc., (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of chronic pain, announced today that it has appointed Michael D. Becker as senior vice president of finance and corporate development, effective immediately.

Mr. Becker brings more than 20 years of experience as a C-level industry executive and Wall Street securities analyst. Most recently, he was founder and president of the consulting firm MDB Communications LLC. In this position, he acted as a strategic advisor and partner servicing the life sciences industry by providing a full range of investor relations and public relations services to enhance client visibility and branding.

“We are very pleased to have Michael joining us as senior vice president of finance and corporate development,” said Sergio Traversa, CEO of Relmada. “He brings strong financial leadership and a wealth of industry experience to the company and is well-suited to lead our corporate development efforts during the continued evolution of Relmada. As a key member of our leadership team, Michael will be a tremendous asset as we approach planned clinical milestones and prepare to apply for uplisting on the NASDAQ Capital Market as soon as feasible.”

Mr. Becker previously served as president, chief executive officer, and member of the board of directors for publicly traded biotechnology companies including commercial-stage Cytogen Corporation (acquired by EUSA Pharma). He held positions of increasing responsibility prior to being appointed president and CEO of Cytogen in 2002, including vice president of business development, industry and investor relations and CEO of AxCell Biosciences, a subsidiary of Cytogen. Prior to his industry career, Mr. Becker spent 9 years in the financial services industry, which includes positions at Wayne Hummer Investments LLC, Kidder, Peabody & Co., Gruntal & Co., and Kemper Securities. He completed coursework in Political Science at DePaul University and received an Associate of Science degree from the Art Institute of Pittsburgh.

“I am very excited to join the Relmada team,” said Mr. Becker. “With a strong balance sheet, impressive scientific expertise, and ambitious strategy, I see tremendous potential for the Company and its diverse pipeline of pain treatment products. I look forward to working with the Relmada team to realize the full potential of this dynamic platform.”

### **About Relmada Therapeutics Inc.**

Relmada Therapeutics is a clinical-stage, publicly traded specialty pharmaceutical company developing novel versions of proven drug products together with new chemical entities that potentially address areas of high unmet medical need in the treatment of pain. The Company has a diversified portfolio of four lead products at various stages of

development including LevoCap ER, its abuse resistant, sustained release dosage form of the opioid analgesic levorphanol; d-methadone, its N-methyl-D-aspartate (NMDA) receptor antagonist for neuropathic pain; BuTab ER, its oral dosage form of the opioid analgesic buprenorphine; and MepiGel, its orphan drug designated topical formulation of the local anesthetic mepivacaine. The Company's product development efforts are guided by the internationally recognized scientific expertise of its research team. The Company's approach is expected to reduce clinical development risks and costs while potentially delivering valuable products in areas of high unmet medical needs. For more information, please visit Relmada's website at: [www.relmada.com](http://www.relmada.com)

### **Forward-Looking Statements**

This news release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause actual results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential, or financial performance. No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Relmada undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.

### **Contact**

Michael Becker, SVP of Finance and Corporate Development  
Relmada Therapeutics Inc.  
Tel: 212-702-7169  
[mbecker@relmada.com](mailto:mbecker@relmada.com)